Published in J Natl Cancer Inst on November 01, 2006
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol (2010) 2.35
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol (2009) 2.09
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol (2008) 1.78
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int (2012) 1.68
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology (2010) 1.64
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int (2009) 1.59
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology (2011) 1.51
Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study. Mayo Clin Proc (2012) 1.46
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology (2007) 1.36
A Bayesian semiparametric survival model with longitudinal markers. Biometrics (2009) 1.29
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol (2009) 1.26
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol (2009) 1.13
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med (2014) 1.11
Screening for prostate cancer: an update. Can J Urol (2008) 1.11
Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol (2011) 1.09
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn (2009) 1.04
Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res (2010) 1.01
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate (2011) 0.97
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br J Cancer (2011) 0.97
Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer. J Natl Compr Canc Netw (2013) 0.93
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer. Cancer Epidemiol (2011) 0.92
PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol (2012) 0.89
Prostate-specific antigen screening: pro. Curr Opin Urol (2010) 0.88
Epidemiology of prostate cancer and treatment remarks. World J Radiol (2012) 0.87
The role of lymphadenectomy in high risk prostate cancer. World J Urol (2008) 0.86
Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys (2008) 0.86
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol (2013) 0.85
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? J Urol (2014) 0.85
Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw (2010) 0.84
Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. BJU Int (2010) 0.83
Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006. Prev Chronic Dis (2011) 0.82
Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. World J Urol (2010) 0.81
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer (2011) 0.81
A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol (2012) 0.80
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol (2008) 0.80
Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts. Int J Clin Exp Med (2013) 0.79
Prostate cancer: is PSA velocity useful? Nat Rev Urol (2009) 0.78
The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. Eur Urol (2008) 0.78
A longitudinal study of PSA and its influential factors in a cohort of Chinese men with initial PSA levels less than 4 ng ml(-1). Asian J Androl (2013) 0.78
Kallikreins as biomarkers for prostate cancer. Biomed Res Int (2014) 0.77
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol (2014) 0.77
Prostate cancer: utility of the risk indicator model in screening. Nat Rev Urol (2010) 0.76
Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian J Androl (2012) 0.76
Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. J Urol (2010) 0.76
Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years. Asian J Androl (2009) 0.76
Prostate-specific antigen and prostate cancer prognosis. J Natl Cancer Inst (2006) 0.76
Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2007) 0.75
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75
Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer. Rev Urol (2014) 0.75
Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer. Turk J Urol (2017) 0.75
PSA Velocity in Risk Stratification of Prostate Cancer. Rev Urol (2013) 0.75
Words of wisdom. Re: detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. Eur Urol (2007) 0.75
Can PSA velocity predict risk of death in men with prostate cancer? Nat Clin Pract Urol (2007) 0.75
Effect of heamolysis on prostate-specific antigen. ISRN Urol (2012) 0.75
Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective. Indian J Surg Oncol (2017) 0.75
New Prognostic Markers: The Pathway from Research to Clinical Practice. Grand rounds Urol (2009) 0.75
Prostate-Cancer Risk Stratification via Early PSA Testing. Rev Urol (2007) 0.75
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. World J Urol (2016) 0.75
"Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol (2017) 0.75
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology (1999) 2.41
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst (2005) 2.15
Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA (2000) 1.89
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol (1994) 1.81
Prostate cancers in men with low PSA levels--must we find them? N Engl J Med (2004) 1.52
PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am (1993) 1.33
Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis (2000) 1.30
More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology (2006) 1.28
Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology (2005) 1.24
Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem (1987) 1.19
Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol (1997) 1.11
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Gait speed and survival in older adults. JAMA (2011) 15.01
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci (2004) 12.46
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet (2010) 8.74
Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci (2006) 8.00
Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc (2006) 6.81
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood (2004) 5.86
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985) (2003) 5.73
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med (2010) 5.20
Frailty: an emerging research and clinical paradigm--issues and controversies. J Gerontol A Biol Sci Med Sci (2007) 4.98
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet (2008) 4.75
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
Hearing loss and incident dementia. Arch Neurol (2011) 4.65
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA (2004) 4.27
Hearing loss and cognitive decline in older adults. JAMA Intern Med (2013) 4.25
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Hearing loss prevalence in the United States. Arch Intern Med (2011) 4.22
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci (2004) 3.96
Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94
Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes (2008) 3.76
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med (2009) 3.71
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Hearing loss prevalence and risk factors among older adults in the United States. J Gerontol A Biol Sci Med Sci (2011) 3.63
Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care (2008) 3.54
Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc (2004) 3.48
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet (2009) 3.38
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. J Am Geriatr Soc (2003) 3.30
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet (2007) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci (2009) 3.14
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08
Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med (2013) 3.08
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01
Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology (2007) 2.98
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol (2004) 2.91
Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med (2007) 2.88
Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci (2006) 2.85
The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci (2014) 2.84
Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci (2012) 2.82
Uric acid and inflammatory markers. Eur Heart J (2006) 2.81
The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. J Urol (2007) 2.78
Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry (2003) 2.77
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Executive function correlates with walking speed in older persons: the InCHIANTI study. J Am Geriatr Soc (2005) 2.75
Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol (2008) 2.75
Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med (2006) 2.73
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73